Fintel reports that on April 21, 2025, B of A Securities upgraded their outlook for United Therapeutics (NasdaqGS:UTHR) from ...

As previously reported, BofA analyst Jason Gerberry upgraded United Therapeutics (UTHR) to Neutral from Underperform with an unchanged price ...

BofA upgraded United Therapeutics (UTHR) to Neutral from Underperform with a $314 price target Stay Ahead of the Market: Discover ...

Patterson is a registered nurse and executive director of a consulting firm that supports OPTN contracts.

Treatment options are limited for those with sudden liver failure and the condition has a death rate as high as 50%.

For the first time since 2016, I enjoyed time with friends and family without planning around dialysis treatments,” the patient said in a statement.

Regulus Therapeutics Inc.’s RGLS share price has surged by 5.41%, which has investors questioning if this is right time to sell.

They look like human organs, they work like human organs ... The Food and Drug Administration has given United Therapeutics ...

U.S. researchers are about to test if livers from gene-edited pigs could treat people with sudden liver failure — not with a ...

In March, two biotechnology companies were given the greenlight by the Food and Drug Administration, or FDA, to conduct ...

Nearly 110,000 people in the United States are awaiting life-saving transplants right now. More than 2,500 of them are Ohioans. The organ shortage continues to grow at a staggering rate ...